tradingkey.logo

Quanterix Corp

QTRX

5.430USD

-0.150-2.69%
Close 09/19, 16:00ETQuotes delayed by 15 min
211.08MMarket Cap
LossP/E TTM

Quanterix Corp

5.430

-0.150-2.69%

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
88 / 207
Overall Ranking
197 / 4720
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 4 analysts
Hold
Current Rating
6.250
Target Price
+12.01%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Quanterix Corporation is a life sciences company. The Company is engaged in developing ultra-sensitive digital immunoassay platforms that advance precision health for life sciences research and diagnostics. Its platforms are based on its digital Simoa detection technology. Its Simoa bead-based and planar array platforms enable customers to detect protein biomarkers in low concentrations in blood, serum, and other fluids. The Company's Simoa technology is based on traditional enzyme-linked immunosorbent assay (ELISA) technology. Its products include HD-X, SR-X, SP-X, Simoa assays and consumables, and NfL antibodies and NfL ELISA kits. It also offers contract research services for customers through its Accelerator Laboratory, which provides customers with access to Simoa technology and supports multiple projects and services, including sample testing, homebrew assay development and custom assay development. It has completed over 2,200 projects for 480 customers using its Simoa platforms.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 30.23% year-on-year.
Overvalued
The company’s latest PE is -2.98, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 36.46M shares, decreasing 26.22% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 2.53M shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.86, which is lower than the Healthcare Equipment & Supplies industry's average of 7.32. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 24.48M, representing a year-over-year decrease of 28.81%, while its net profit experienced a year-over-year decrease of 306.29%.

Score

Industry at a Glance

Previous score
6.86
Change
0

Financials

9.34

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data

Quality of Earnings

6.61

Operational Efficiency

6.57

Growth Potential

4.71

Shareholder Returns

7.09

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Healthcare Equipment & Supplies industry's average of 3.59. Its current P/E ratio is -3.06, which is 67.41% below the recent high of -5.13 and -382.57% above the recent low of -14.79.

Score

Industry at a Glance

Previous score
2.80
Change
1.2

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 88/207
No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 6.00, which is lower than the Healthcare Equipment & Supplies industry's average of 7.70. The average price target for Quanterix Corp is 6.50, with a high of 7.00 and a low of 5.00.

Score

Industry at a Glance

Previous score
6.00
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 4 analysts
Hold
Current Rating
6.250
Target Price
+12.01%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

94
Total
4
Median
7
Average
Company name
Ratings
Analysts
Quanterix Corp
QTRX
4
Boston Scientific Corp
BSX
36
Edwards Lifesciences Corp
EW
35
Intuitive Surgical Inc
ISRG
34
Veeva Systems Inc
VEEV
32
Thermo Fisher Scientific Inc
TMO
31
1
2
3
...
19

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 8.46, which is higher than the Healthcare Equipment & Supplies industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 6.04 and the support level at 4.68, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
8.46
Change
-0.17

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(2)
Neutral(2)
Buy(1)
Indicators
Value
Direction
MACD(12,26,9)
0.308
Neutral
RSI(14)
61.195
Neutral
STOCH(KDJ)(9,3,3)
87.985
Overbought
ATR(14)
0.292
High Vlolatility
CCI(14)
130.098
Buy
Williams %R
13.235
Overbought
TRIX(12,20)
-0.024
Sell
StochRSI(14)
61.880
Sell
Moving Average
Sell(2)
Neutral(0)
Buy(4)
Indicators
Value
Direction
MA5
5.304
Buy
MA10
4.926
Buy
MA20
4.743
Buy
MA50
5.157
Buy
MA100
5.435
Sell
MA200
6.927
Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 7.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.89. The latest institutional shareholding proportion is 81.18%, representing a quarter-over-quarter decrease of 22.08%. The largest institutional shareholder is The Vanguard, holding a total of 2.53M shares, representing 5.44% of shares outstanding, with 5.09% decrease in holdings.

Score

Industry at a Glance

Previous score
7.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
Portolan Capital Management, L.L.C.
2.96M
+14.51%
Columbia Threadneedle Investments (UK)
3.00M
+8.60%
BlackRock Institutional Trust Company, N.A.
2.68M
-3.21%
The Vanguard Group, Inc.
Star Investors
2.53M
+14.32%
Kent Lake PR LLC
2.92M
+10.58%
Walt (David R)
1.86M
+24.84%
Invenomic Capital Management LP
902.04K
+153.83%
William Blair Investment Management, LLC
1.11M
+4.14%
Columbia Threadneedle Investments (US)
716.23K
+61.14%
Easterly Investment Partners LLC
1.33M
+38.81%
1
2

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.07, which is lower than the Healthcare Equipment & Supplies industry's average of 3.87. The company's beta value is 1.05. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

Score

Industry at a Glance

Previous score
3.07
Change
0
Beta vs S&P 500 index
1.07
VaR
+7.06%
240-Day Maximum Drawdown
+72.19%
240-Day Volatility
+83.09%
Return
Best Daily Return
60 days
+10.94%
120 days
+30.04%
5 years
+33.66%
Worst Daily Return
60 days
-13.79%
120 days
-19.02%
5 years
-54.76%
Sharpe Ratio
60 days
-0.28
120 days
+0.08
5 years
-0.13
Risk Assessment
Maximum Drawdown
240 days
+72.19%
3 years
+85.07%
5 years
+95.28%
Return-to-Drawdown Ratio
240 days
-0.77
3 years
-0.18
5 years
-0.19
Skewness
240 days
+0.28
3 years
+0.83
5 years
-0.41
Volatility
Realised Volatility
240 days
+83.09%
5 years
+81.53%
Standardised True Range
240 days
+9.95%
5 years
+30.63%
Downside Risk-Adjusted Return
120 days
+11.62%
240 days
+11.62%
Maximum Daily Upside Volatility
60 days
+59.80%
Maximum Daily Downside Volatility
60 days
+63.54%
Liquidity
Average Turnover Rate
60 days
+2.04%
120 days
+1.97%
5 years
--
Turnover Deviation
20 days
+49.24%
60 days
+48.38%
120 days
+43.11%

Peer Comparison

Healthcare Equipment & Supplies
Quanterix Corp
Quanterix Corp
QTRX
6.18 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Insulet Corp
Insulet Corp
PODD
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
STERIS plc
STERIS plc
STE
8.33 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Stevanato Group SpA
Stevanato Group SpA
STVN
8.24 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Abbott Laboratories
Abbott Laboratories
ABT
8.13 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Transmedics Group Inc
Transmedics Group Inc
TMDX
8.01 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI